Mednax, Inc. (MD) Files Form 4 Insider Selling : David A. Clark Sells 11,470 Shares

Mednax, Inc. (MD): David A. Clark , President, Western Division of Mednax, Inc. sold 11,470 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $67.78 per share for a total value of $777,465.25 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Michael D Stanley (President, Clinical Services) sold 14,778 shares at $67.78 per share price.On Jun 3, 2016, Joseph M Calabro (President and COO) sold 28,347 shares at $67.78 per share price.Also, On May 17, 2016, Dominic J Andreano (SVP, General Counsel and Secy) sold 3,000 shares at $68.53 per share price.On May 2, 2016, Vivian Lopez-blanco (Chief Financial Officer) sold 9,350 shares at $71.22 per share price.

Shares of MEDNAX Inc (MD) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.81 points or -1.19% at $67.5 with 3,45,501 shares getting traded. Post opening the session at $68.31, the shares hit an intraday low of $67.19 and an intraday high of $68.31 and the price vacillated in this range throughout the day. The company has a market cap of $6,279 M and the number of outstanding shares has been calculated to be 9,30,25,460 shares. The 52-week high of MEDNAX Inc is $86.09 and the 52-week low is $61.4.

MEDNAX Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.MEDNAX Inc is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 79 from a previous price target of $75 .The Rating was issued on Apr 29, 2016.MEDNAX Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 76 from a previous price target of $81 . The Rating was issued on Mar 8, 2016.MEDNAX Inc is Downgraded by Susquehanna to Neutral. Earlier the firm had a rating of Positive on the company shares. The Rating was issued on Mar 7, 2016.

MEDNAX Inc. (MEDNAX) is a provider of physician services including newborn maternal-fetal and other pediatric subspecialty care. The Company provides clinical care to babies born prematurely or with complications within specific hospital units primarily neonatal intensive care units (NICUs). It provides anesthesia care at more than 90 hospitals 100 ambulatory surgery centers and office-based practices with over 950 of its affiliated anesthesiologists. It provides acute and chronic pain management services in over 20 pain management centers through its network of physicians and physician assistants. It provides inpatient and office-based clinical care to expectant mothers and their unborn babies through its over 245 affiliated maternal-fetal medicine subspecialists as well as obstetricians and other clinicians. Its network includes other pediatric subspecialists such as pediatric intensivists pediatric hospitalists and pediatric surgeons.

Leave a Reply

MEDNAX Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on MEDNAX Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.